African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitis
Maryam Yazdanfar(University of California, Davis), Christopher L. Bowlus(University of California, Davis), Barry Schlansky(Kaiser Permanente), Raffi Karagozian(Tufts Medical Center), Joseph Zepeda(University of California, Davis), Aldo J. Montaño‐Loza(University of Alberta), Lei Yu(University of Alberta), David N. Assis(Yale University), Craig Lammert(Indiana University – Purdue University Indianapolis), K. Rajender Reddy(Hospital of the University of Pennsylvania), Ellina Lytvyak(University of Alberta), Stuart C. Gordon(United States Department of Veterans Affairs), Richard Dean(University of California, Davis), Jialin Wu(Sun Yat-sen University), Daniel S. Pratt(University of Colorado Denver), Cynthia Levy(University of Miami), Shaun Chandna(University of Utah), Bilal Hameed(University of California, San Francisco), Joshua R. Korzenik(Harvard University), Joseph Ahn(Mayo Clinic), Stacey Prenner(University of Pennsylvania), Elizabeth J. Carey(Mayo Clinic in Arizona), Lisa Forman(Center for Clinical Research (United States)), David S. Goldberg(University of Miami)
Cited by 7
Related Papers
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k